Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
mg) with a 26-week steroid taper regimen achieved sustained remission from week 12 through week 52 compared to 29 percent of patients receiving placebo with a 52-week steroid taper regimen - The safety profile in GCA was generally consistent with that in approved indications, and no new safety signals were identified - The clinical program reflects AbbVie's history of developing new treatment options for patients with immune-mediated diseases, where there remains significant unmet medical need NORTH CHICAGO, Ill. April 18, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ ® ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission a from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Global $11 Billion Non-Hodgkin Lymphoma Market Outlook, 2024-2029: Focus on T-cell Lymphoma and Immunotherapies [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Could Be a Great Choice [Yahoo! Finance]Yahoo! Finance
- 3 Top Dividend Stocks to Maximize Your Retirement Income [Yahoo! Finance]Yahoo! Finance
- AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Earnings Beat: AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 4/26/24 - Form 8-K
- 4/3/24 - Form 8-K
- 4/2/24 - Form 4
- ABBV's page on the SEC website